IL156830A0 - Pharmaceutical compositions which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer - Google Patents

Pharmaceutical compositions which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer

Info

Publication number
IL156830A0
IL156830A0 IL15683002A IL15683002A IL156830A0 IL 156830 A0 IL156830 A0 IL 156830A0 IL 15683002 A IL15683002 A IL 15683002A IL 15683002 A IL15683002 A IL 15683002A IL 156830 A0 IL156830 A0 IL 156830A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
solid dispersion
hydroxypropylmethylcellulose phthalate
phthalate polymer
polymer
Prior art date
Application number
IL15683002A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL156830A0 publication Critical patent/IL156830A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15683002A 2001-02-27 2002-02-25 Pharmaceutical compositions which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer IL156830A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0104752.1A GB0104752D0 (en) 2001-02-27 2001-02-27 Pharmaceutical compositions
PCT/SE2002/000327 WO2002067904A1 (fr) 2001-02-27 2002-02-25 Composition pharmaceutique comprenant une dispersion solide de polymere hydroxypropylmethylcellulose-phthalate

Publications (1)

Publication Number Publication Date
IL156830A0 true IL156830A0 (en) 2004-02-08

Family

ID=9909545

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15683002A IL156830A0 (en) 2001-02-27 2002-02-25 Pharmaceutical compositions which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer

Country Status (14)

Country Link
US (1) US20040138231A1 (fr)
EP (1) EP1365746A1 (fr)
JP (1) JP2004527489A (fr)
KR (1) KR20040011469A (fr)
CN (1) CN1533268A (fr)
BR (1) BR0206960A (fr)
CA (1) CA2435815A1 (fr)
GB (1) GB0104752D0 (fr)
IL (1) IL156830A0 (fr)
MX (1) MXPA03006746A (fr)
NO (1) NO20033782D0 (fr)
NZ (1) NZ527080A (fr)
WO (1) WO2002067904A1 (fr)
ZA (1) ZA200305386B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2004105728A2 (fr) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Dispersions solides de cefpodoxime-proxetil et leurs procedes de preparation
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびhpmcasを含む固体分散物中の経口用薬学的組成物
LT2346495T (lt) * 2008-10-07 2016-10-10 Astrazeneca Uk Limited Farmacinė kompozicija 514
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺
RS63751B1 (sr) 2016-09-30 2022-12-30 Salix Pharmaceuticals Inc Čvrsti disperzioni oblici rifaksimina

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
TW212139B (fr) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
EP0717988B1 (fr) * 1993-08-20 2001-10-17 Nippon Shinyaku Company, Limited Preparation restant dans l'estomac, forme moulee gonflee, et procede de preparation
JP2002513790A (ja) * 1998-05-02 2002-05-14 アストラゼネカ アクチボラグ Xa因子を阻害する複素環誘導体
JP5159012B2 (ja) * 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物

Also Published As

Publication number Publication date
ZA200305386B (en) 2004-10-11
MXPA03006746A (es) 2003-10-24
NO20033782L (no) 2003-08-26
GB0104752D0 (en) 2001-04-18
NZ527080A (en) 2005-02-25
NO20033782D0 (no) 2003-08-26
JP2004527489A (ja) 2004-09-09
EP1365746A1 (fr) 2003-12-03
KR20040011469A (ko) 2004-02-05
US20040138231A1 (en) 2004-07-15
WO2002067904A1 (fr) 2002-09-06
CN1533268A (zh) 2004-09-29
BR0206960A (pt) 2004-03-09
CA2435815A1 (fr) 2002-09-06

Similar Documents

Publication Publication Date Title
HK1072200A1 (en) Pro-micelle pharmaceutical compositions
GB2389530B (en) Pharmaceutical compositions
PL363507A1 (en) Pharmaceutical uses of bisphosphonates
HK1081457A1 (en) Dispersible pharmaceutical compositions
GB0319041D0 (en) Pharmaceutical Formulations
AU2002313236A1 (en) Medicinal compositions
IL175973A0 (en) Pharmaceutical compositions comprising lercanidipine
HK1065944A1 (en) Medicinal compositions
AU2002341205A1 (en) Pharmaceutical compositions comprising cyclosporin
AU2002337803A1 (en) Sustained release pharmaceutical compositions
GB2391473B (en) Pharmaceutical compositions
HUP0400850A3 (en) Oral pharmaceutical compositions
IL156830A0 (en) Pharmaceutical compositions which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer
GB0120701D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
AU2002351739A1 (en) Solid dose micro implant
GB0105560D0 (en) Pharmaceutical formulations
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
GB0213481D0 (en) Pharmaceutical compositions
GB2382302B (en) Pharmaceutical compositions
GB0107540D0 (en) Polymer compositions
PL370907A1 (en) Pharmaceutical compositions
AU2002346223A1 (en) Medicinal compositions
GB0126732D0 (en) Pharmaceutical compositions